HC Wainwright Has Positive Forecast for KALV FY2027 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities researchers at HC Wainwright boosted their FY2027 earnings per share estimates for KalVista Pharmaceuticals in a report released on Thursday, March 12th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will earn $0.84 per share for the year, up from their prior forecast of $0.82. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

Several other brokerages also recently commented on KALV. Needham & Company LLC lifted their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $16.94 on Friday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a fifty day simple moving average of $15.76 and a 200 day simple moving average of $14.27. The company has a market cap of $856.32 million, a P/E ratio of -4.29 and a beta of -0.35. KalVista Pharmaceuticals has a 1 year low of $9.23 and a 1 year high of $19.00.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in KALV. The Manufacturers Life Insurance Company increased its stake in KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after acquiring an additional 818 shares during the period. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Rhumbline Advisers grew its holdings in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in shares of KalVista Pharmaceuticals by 26.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock valued at $110,000 after purchasing an additional 2,061 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of KalVista Pharmaceuticals by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock valued at $5,239,000 after purchasing an additional 2,402 shares during the period.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $61,890.75. Following the sale, the insider directly owned 47,003 shares in the company, valued at $731,836.71. This trade represents a 7.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $156,229.38. Following the transaction, the chief executive officer owned 442,883 shares in the company, valued at approximately $6,895,688.31. The trade was a 2.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 33,378 shares of company stock valued at $522,290 in the last 90 days. 4.30% of the stock is owned by company insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.